Brazilian trial challenges standard: can one year of treatment match two?
NCT ID NCT07376317
Summary
This study is testing if a shorter, one-year course of pembrolizumab immunotherapy works as well as the standard two-year course for people with advanced melanoma that has spread or returned. It aims to make this effective treatment more accessible and affordable within Brazil's public health system. Researchers will follow 29 patients to see if the cancer stays controlled and measure quality of life and costs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ICESP
São Paulo, São Paulo, 01246000, Brazil
Conditions
Explore the condition pages connected to this study.